HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Characterization of DNA demethylation in normal and cancerous cell lines and the regulatory role of cell cycle proteins in human DNA demethylase activity.

Abstract
DNA methylation/demethylation constitutes a major consequence in all biological processes involving transcription, differentiation, development, DNA repair, recombination, and chromosome organization. Our earlier studies established that demethylation of CpG rich sequence by human DNA demethylase activity (5-methylcytosine-DNA glycosylase (5MeC-DNA glycosylase)) resembles "base excision DNA repair activity" and creates single-strand breaks on DNA that is associated with proliferating cell nuclear antigen (PCNA). Here in this report, we have identified differential DNA demethylation targets (hemi-methylated vs. fully-methylated) in normal cell lines and cancerous cell lines, and a shortened G(0)/G(1) resting time in cancerous cell lines than the normal cell lines. We have identified that in normal HFL1 fibroblast cell line, DNA demethylase activity targets hemi-methylated CpG specific sites on DNA. This normal cell line DNA demethylase activity associates with PCNA immune complex that is inhibited by CDKI proteins p21(waf1)/Gadd45alpha and Gadd45beta. While in cancerous LnCap and BT20 cell lines DNA demethylase activity targets fully-methylated CpG specific sites on DNA. This cancer cell line DNA demethylase activity is not associated with PCNA immune complex and is not inhibited by CDKI proteins p21(waf1)/Gadd45alpha and Gadd45beta. We have also identified that the fully-methylated CpG specific DNA demethylase activity from cancerous cell lines to associate with p300/CBP protein. These significant observations of variable targets of DNA demethylation and alternate partner proteins for DNA demethylase activity in cancerous cell lines are discussed in terms of double-strand DNA breaks versus single-strand DNA breaks and their role in the exit of G(1)/G(2) cell cycle stages. Also, the inability of cell cycle regulatory proteins like PCNA, p21(waf1), and Gadd45 to control DNA demethylase activity in cancerous cell lines is discussed in terms of accelerated G(1)/G(2) cell cycle stage exit to facilitate unregulated cellular proliferation, loss of control of chromosomal organization, and the development of oncogenesis in cancerous cell lines.
AuthorsMariappan Vairapandi
JournalJournal of cellular biochemistry (J Cell Biochem) Vol. 91 Issue 3 Pg. 572-83 (Feb 15 2004) ISSN: 0730-2312 [Print] United States
PMID14755686 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2003 Wiley-Liss, Inc.
Chemical References
  • Antigens, Differentiation
  • CDKN1A protein, human
  • Cell Cycle Proteins
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins
  • GADD45A protein, human
  • GADD45B protein, human
  • Nuclear Proteins
  • Proliferating Cell Nuclear Antigen
  • Radioactive Tracers
  • Trans-Activators
  • Aphidicolin
  • DNA
  • Oxidoreductases, O-Demethylating
  • methyl-CpG DNA demethylase
  • Cyclin-Dependent Kinases
  • Deoxyribonuclease HpaII
  • Paclitaxel
Topics
  • Antigens, Differentiation (pharmacology)
  • Aphidicolin (pharmacology)
  • Blotting, Western
  • Cell Cycle (physiology)
  • Cell Cycle Proteins (physiology)
  • Cell Line
  • Cell Line, Tumor
  • CpG Islands (genetics)
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclin-Dependent Kinases (antagonists & inhibitors)
  • Cyclins (pharmacology)
  • DNA (genetics, metabolism)
  • DNA Methylation
  • Deoxyribonuclease HpaII (metabolism)
  • Female
  • Fibroblasts (enzymology, physiology)
  • Flow Cytometry
  • Gene Expression Regulation, Enzymologic
  • Humans
  • Interphase (physiology)
  • Male
  • Nuclear Proteins (immunology, metabolism, pharmacology)
  • Oxidoreductases, O-Demethylating (genetics, metabolism)
  • Paclitaxel (pharmacology)
  • Proliferating Cell Nuclear Antigen (immunology, metabolism)
  • Radioactive Tracers
  • Trans-Activators (immunology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: